Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*

Background: An elevated level of low-density lipoprotein cholesterol (LDL-C) constitutes one of the most important modifiable risk factors for cardiovascular disease (CVD). Individuals with heterozygous familial hypercholesterolaemia (HeFH) are particularly vulnerable to CVD events. The addition of...

Descripción completa

Detalles Bibliográficos
Autores principales: Borissov, Borislav, Urbich, Michael, Georgieva, Boryana, Tsenov, Svetoslav, Villa, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757229/
https://www.ncbi.nlm.nih.gov/pubmed/29321830
http://dx.doi.org/10.1080/20016689.2017.1412753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757229/
https://www.ncbi.nlm.nih.gov/pubmed/29321830
http://dx.doi.org/10.1080/20016689.2017.1412753

Ejemplares similares